Literature DB >> 31109978

Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro.

Lais Pessanha de Carvalho1,2,3, Thaisa Lucas Sandri1,2,4, Edésio José Tenório de Melo3, Rolf Fendel1,2,5, Peter G Kremsner1,2,5, Benjamin Mordmüller1,2,5, Jana Held6,2,5.   

Abstract

Ivermectin is the drug of choice for many parasitic infections, with more than one billion doses being distributed in onchocerciasis programs. The drug has been put into focus recently by the malaria community because of its potential to kill blood-sucking mosquitoes, thereby reducing malaria transmission. However, the activity of ivermectin against the malaria parasite itself has been only partly investigated. This study aimed to investigate the in vitro activity of ivermectin against asexual and sexual stages of Plasmodium falciparum Both asexual and late-stage gametocytes were incubated with ivermectin and control drugs in vitro The growth-inhibiting effects were assessed for asexual stages of different Plasmodium falciparum laboratory strains and culture-adapted clinical isolates using the histidine-rich protein 2 enzyme-linked immunosorbent assay technique. The effect against stage IV/V gametocytes was evaluated based on ATP quantification. Ivermectin showed activities at nanomolar concentrations against asexual stages (50% inhibitory concentration of ∼100 nM) and stage IV/V gametocytes (500 nM) of P. falciparum Stage-specific assays suggested that ivermectin arrests the parasite cycle at the trophozoite stage. Ivermectin might add a feature to its "wonder drug" properties with activity against asexual stages of the malaria parasite Plasmodium falciparum The observed activities might be difficult to reach with current regimens but will be more relevant with future high-dose regimens under investigation. Further studies should be performed to confirm these results in vitro and in vivo.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Plasmodium falciparumzzm321990; antimalarial agents; gametocyte

Mesh:

Substances:

Year:  2019        PMID: 31109978      PMCID: PMC6658753          DOI: 10.1128/AAC.00085-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  74 in total

Review 1.  Ivermectin as an antiparasitic agent for use in humans.

Authors:  W C Campbell
Journal:  Annu Rev Microbiol       Date:  1991       Impact factor: 15.500

Review 2.  Permethrin and ivermectin for scabies.

Authors:  Bart J Currie; James S McCarthy
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

3.  Ivermectin as a complementary strategy to kill mosquitoes and stop malaria transmission?

Authors:  Richard W Steketee; Feiko O Ter Kuile
Journal:  Clin Infect Dis       Date:  2014-11-19       Impact factor: 9.079

4.  Nascent RNA sequencing reveals mechanisms of gene regulation in the human malaria parasite Plasmodium falciparum.

Authors:  Xueqing Maggie Lu; Gayani Batugedara; Michael Lee; Jacques Prudhomme; Evelien M Bunnik; Karine G Le Roch
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

5.  Lethal and sublethal effects of avermectin/milbemycin parasiticides on the African malaria vector, Anopheles arabiensis.

Authors:  Megan L Fritz; Edward D Walker; James R Miller
Journal:  J Med Entomol       Date:  2012-03       Impact factor: 2.278

6.  Plasmodium falciparum gametocytes: their longevity and infectivity.

Authors:  M E Smalley; R E Sinden
Journal:  Parasitology       Date:  1977-02       Impact factor: 3.234

7.  Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.

Authors:  Menno R Smit; Eric O Ochomo; Ghaith Aljayyoussi; Titus K Kwambai; Bernard O Abong'o; Tao Chen; Teun Bousema; Hannah C Slater; David Waterhouse; Nabie M Bayoh; John E Gimnig; Aaron M Samuels; Meghna R Desai; Penelope A Phillips-Howard; Simon K Kariuki; Duolao Wang; Steve A Ward; Feiko O Ter Kuile
Journal:  Lancet Infect Dis       Date:  2018-03-27       Impact factor: 25.071

8.  In Vitro Effects of Ivermectin and Sulphadiazine on Toxoplasma gondii.

Authors:  Melek Bilgin; Tuba Yıldırım; Murat Hökelek
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

9.  Potential causes and consequences of behavioural resilience and resistance in malaria vector populations: a mathematical modelling analysis.

Authors:  Gerry F Killeen; Nakul Chitnis
Journal:  Malar J       Date:  2014-03-14       Impact factor: 2.979

10.  Ivermectin and malaria control.

Authors:  Satoshi Ōmura; Andy Crump
Journal:  Malar J       Date:  2017-04-24       Impact factor: 2.979

View more
  10 in total

1.  Effects of combined drug treatments on Plasmodium falciparum: In vitro assays with doxycycline, ivermectin and efflux pump inhibitors.

Authors:  Riccardo Nodari; Yolanda Corbett; Ilaria Varotto-Boccazzi; Daniele Porretta; Donatella Taramelli; Sara Epis; Claudio Bandi
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

Review 2.  Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action.

Authors:  Lais Pessanha de Carvalho; Andrea Kreidenweiss; Jana Held
Journal:  Molecules       Date:  2021-04-15       Impact factor: 4.411

Review 3.  Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development.

Authors:  Takuro Endo; Hitoshi Takemae; Indu Sharma; Tetsuya Furuya
Journal:  Front Cell Infect Microbiol       Date:  2021-12-24       Impact factor: 5.293

4.  Boromycin has Rapid-Onset Antibiotic Activity Against Asexual and Sexual Blood Stages of Plasmodium falciparum.

Authors:  Laís Pessanha de Carvalho; Sara Groeger-Otero; Andrea Kreidenweiss; Peter G Kremsner; Benjamin Mordmüller; Jana Held
Journal:  Front Cell Infect Microbiol       Date:  2022-01-14       Impact factor: 5.293

5.  Synthesis and antiplasmodial activity of regioisomers and epimers of second-generation dual acting ivermectin hybrids.

Authors:  Lovepreet Singh; Diana Fontinha; Denise Francisco; Miguel Prudêncio; Kamaljit Singh
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.996

6.  Broadening the spectrum of ivermectin: Its effect on Trypanosoma cruzi and related trypanosomatids.

Authors:  Laura Fraccaroli; María Daniela Ruiz; Virginia Gabriela Perdomo; Agustina Nicole Clausi; Darío Emmanuel Balcazar; Luciana Larocca; Carolina Carrillo
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

Review 7.  Repurposing Drugs to Fight Hepatic Malaria Parasites.

Authors:  Diana Fontinha; Isabel Moules; Miguel Prudêncio
Journal:  Molecules       Date:  2020-07-28       Impact factor: 4.411

8.  A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.

Authors:  Peter Billingsley; Fred Binka; Carlos Chaccour; Brian Foy; Silvia Gold; Matiana Gonzalez-Silva; Julie Jacobson; George Jagoe; Caroline Jones; Patrick Kachur; Kevin Kobylinski; Anna Last; James V Lavery; David Mabey; David Mboera; Charles Mbogo; Ana Mendez-Lopez; N. Regina Rabinovich; Sarah Rees; Frank Richards; Cassidy Rist; Jessica Rockwood; Paula Ruiz-Castillo; Jetsumon Sattabongkot; Francisco Saute; Hannah Slater; Andrew Steer; Kang Xia; Rose Zullinger
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

9.  Inhibition of Plasmodium sporogonic stages by ivermectin and other avermectins.

Authors:  Raquel Azevedo; António M Mendes; Miguel Prudêncio
Journal:  Parasit Vectors       Date:  2019-11-21       Impact factor: 3.876

10.  Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs.

Authors:  Lukas von Bredow; Thomas Martin Schäfer; Julian Hogenkamp; Maik Tretbar; Daniel Stopper; Fabian B Kraft; Julian Schliehe-Diecks; Andrea Schöler; Arndt Borkhardt; Sanil Bhatia; Jana Held; Finn K Hansen
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.